News | August 24, 2023
Glenmark Pharmaceuticals USA reaches antitrust settlement with DOJ
The company has entered into a three-year Deferred Prosecution Agreement
The company has entered into a three-year Deferred Prosecution Agreement
Erdafitinib is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma
Patent Term Extension is designed to restore some of the patent life lost during the regulatory review process for new drugs.
The judicial response to industry lawsuits on drug pricing regulations have been mixed in the past
Agilent respectfully disagrees with the PTAB’s opinion of unpatentability in view of prior art previously considered by the USPTO during its primary examination
Mindset disagrees with and denies the allegations set forth from Reunion.
N-nitroso dimethylamine (NDMA) is a probable human carcinogen and tts effects on humans rely on observational studies.
Olaparib is indicated primarily for certain forms of ovarian, breast, pancreatic, and prostate cancer
In a time when conversations around mental health have become ever more urgent Vaidya’s work is extremely contextual
Natco Chlorantraniliprole (CTPR) Process does not infringe FMC's Indian Patent 298645.
Subscribe To Our Newsletter & Stay Updated
